F74. CLINICAL SYMPTOMS AND NOT OBJECTIVE COGNITIVE PERFORMANCE DRIVE SUBJECTIVE COGNITIVE COMPLAINTS IN PATIENTS WITH SCHIZOPHRENIA

BACKGROUND: The United States Food and Drug Administration (FDA) recommends that drugs that exert a pro-cognitive effect should be accompanied by measurable improvements in ‘real-world’ functioning. Patients with schizophrenia typically exhibit substantial impairments across a wide range of cognitiv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Schizophr Bull
Autors principals: Cotter, Jack, Granger, Kiri, Evenden, John, Barnett, Jennifer, Sand, Michael
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888865/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sby017.605
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars